biolitec AG
biolitec AG:biolitec AG – group turnover 2009/2010 with Euro 30.4 million at previous year’s level – gross profit increases to Euro 19.5 million – dividend recommended
biolitec AG / Key word(s): Final Results 24.01.2011 17:02 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- biolitec AG - group turnover 2009/2010 with Euro 30.4 million at previous year's level - gross profit increases to Euro 19.5 million - dividend recommended Jena, January 24, 2011 - www.biolitec.de - biolitec AG, listed in the Prime Standard of Frankfurt stock exchange (ISIN DE0005213409), achieved in fiscal year 2009/2010 a group turnover of Euro 30.4 million (previous year: Euro 30.5 million). Turnover of the expired fiscal year has stabilized on previous year's level. Gross profit increased to Euro 19.5 million. The first three quarters were marginally below previous year's results, the 4th quarter reversed the trend with a turnover of Euro 8.51 million, which continued in fiscal year 2010/2011 with an average growth of 15%. Compared with the previous year gross profit increased by Euro 1.1 million to Euro 19.56 million. In 2009/2010 biolitec AG achieved EBIT results of Euro -0.05 million, i. e. Euro 2.55 million above the adjusted results of the previous year (Euro -2.6 million). In comparison with the previous year, inventories have been reduced by Euro 2.6 million. In 2010/2011, a further decrease in inventories is planned. Sales costs have been reduced by almost Euro 4 million to Euro 10.9 million in fiscal year 2009/2010. A new international study yielded very favorable results in 2010 regarding biolitec's cancer drug Foscan(R). 68% of the patients treated with the drug responded well. In more and more European countries national health organisations are making the drug available to patients without additional charges. Foscan(R) is a carrier of hope for patients with head and neck cancer - such as malignant tumors localized at the mouth base, tongue and pharynx; especially for patients for whom no other treatment can be found. The medical LIFETM (Laser Induced Flow Enhancement) laser therapy for prostate treatment as well as the vein treatment ELVeS(R) (Endo Laser Vein System) including the TWISTERTM fibres for BPH and ELVeS(R) RADIAL are mainly responsible for the current turnover and have a very strong expansion potential in world markets. Biolitec AG has applied for a patent for its innovative laser therapy, the photocoagulation of haemorrhoidal arteries with HeLPTM (Haemorrhoid Laser Procedure), a minimally-invasive and painless procedure. Because of stable turnover figures of the previous fiscal year, R&D expenditures - required for long-term growth and profitability of the group - have been maintained at a level of Euro 3.58 million (approx. 12% of turnover). By the end of the fiscal year liquid assets increased to more than Euro 7.9 million, leading to an extremely stable financial situation for biolitec AG. For that reason the executive board and the supervisory board recommend - after approval of the annual financial statements - a dividend of Euro 0.10 per share to the Annual Shareholders' Meeting. Sales of the segment optical fibres/laser probes increased in fiscal year 2009/2010 by Euro 2.37 million to Euro 23.07 million. Turnover in the laser segment amounted to Euro 6.1 million, turnover of the pharma sector added up to Euro 1.2 million. The largest share of biolitec AG's turnover has been generated in Europe and North America. In addition to core markets biolitec sees significant opportunities for its products in Asia, South America and the Middle East. In these markets biolitec has been able to increase turnover by 5.5% in fiscal year 2009/2010. For the current fiscal year an increase of turnover and earnings is expected. 24.01.2011 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: biolitec AG Otto-Schott-Str.15 07745 Jena Deutschland Phone: +49 (0) 3641 519 53 0 Fax: +49 (0) 3641 519 53 33 E-mail: info@biolitec.de Internet: www.biolitec.de ISIN: DE0005213409 WKN: 521340 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden